26 out The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma
Tiempo de lectura: < 1 minuto¡Haz clic para calificar esta publicación!
Debes registrarte para votar
Sorry, the comment form is closed at this time.